Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001209191-19-039526
Filing Date
2019-06-28
Accepted
2019-06-28 17:15:03
Documents
1
Period of Report
2019-06-20

Document Format Files

Seq Description Document Type Size
1 FORM 4 SUBMISSION doc4.html 4  
1 FORM 4 SUBMISSION doc4.xml 4 11724
  Complete submission text file 0001209191-19-039526.txt   13051
Mailing Address 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203
Business Address 2525 WEST END AVENUE SUITE 950 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Issuer) CIK: 0001087294 (see all company filings)

EIN.: 000000000
SIC: 2834 Pharmaceutical Preparations

Mailing Address 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203
Business Address
Bernard Gordon R (Reporting) CIK: 0001470015 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-33637 | Film No.: 19930418